Upregulation of AXL and β-catenin in chronic lymphocytic leukemia cells cultured with bone marrow stroma cells is associated with enhanced drug resistance

Blood Cancer J. 2021 Feb 18;11(2):37. doi: 10.1038/s41408-021-00426-2.

Authors

Affiliations

¹ Division of Hematology, Mayo Clinic, Rochester, MN, USA.
² Tolero Pharmaceuticals, Inc., Lehi, UT, USA.
³ Stephenson Cancer Center and Department of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
⁴ Division of Hematology, Mayo Clinic, Rochester, MN, USA. kay.neil@mayo.edu.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / pharmacology
Axl Receptor Tyrosine Kinase
Cell Line, Tumor
Cells, Cultured
Coculture Techniques
Drug Resistance, Neoplasm*
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell / genetics*
Mesenchymal Stem Cells / cytology
Mesenchymal Stem Cells / drug effects
Proto-Oncogene Proteins / genetics*
Receptor Protein-Tyrosine Kinases / genetics*
Up-Regulation* / drug effects
beta Catenin / genetics*

Substances

Antineoplastic Agents
CTNNB1 protein, human
Proto-Oncogene Proteins
beta Catenin
Receptor Protein-Tyrosine Kinases
Axl Receptor Tyrosine Kinase
AXL protein, human